

18 June 2026

Lung Cancer Figures

Q1. How many non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- **ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib) <5**
- **Amivantamab Monotherapy 0**
- **Atezolizumab monotherapy (any formulation) OR Atezolizumab monotherapy (infusion only) <5**
- **Atezolizumab (any formulation) + Bevacizumab + Carboplatin + Paclitaxel 0**
- **Atezolizumab monotherapy (subcutaneous injection only) 0**
- **Dabrafenib + Trametinib 0**
- **Docetaxel monotherapy or in combination with Carboplatin/Cisplatin <5**
- **Durvalumab <5**
- **Gemcitabine No monotherapy: Combination therapies listed below**
- **Nintedanib + Docetaxel <5**
- **Nivolumab No monotherapy: Combination therapies listed below**
- **Osimertinib 9**
- **Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib) 0**
- **Paclitaxel No monotherapy: Combination therapies listed below**
- **Pembrolizumab Monotherapy 14**
- **Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin) 0**
- **Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin) <5**
- **Pemetrexed + Platinum (Carboplatin/Cisplatin) 5**
- **RET Inhibitors (Pralsetinib, Selpercatinib) 0**
- **Sotorasib <5**
- **Tepotinib 0**
- **Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin 18**
- **Other active systemic anti-cancer therapy** Gemcitabine&Carboplatin <5, Nivolumab/Paclitaxel/Carboplatin <5, Osimertinnib&Pemetrexed/Carboplatin <5, Paclitaxel&Carboplatin <5, Paclitaxel&Carboplatin XRT <5, Pembrolizumab/Gemcitabine/Carboplatin <5.
- **Palliative care only Not available**
- **Amivantamab with carboplatin and pemetrexed 0**
- **Cemiplimab with platinum-based chemotherapy 0**

18 June 2026

- Adagrasib 0
- Datopotamab deruxtecan 0
- Amivantamab with Lazertinib 0
- Pembrolizumab subcutaneous injection 0

Q2. Does your trust participate in any clinical trials for Non-Small Cell Lung Cancer? If so, please provide the name of each trial, and the number of patients taking part.

Open Trials - Belfast Trust 08/06/26		
Project Short title	Project Full title	Recruited (org)
CONCORDE	A platform study of DNA damage response inhibitors in combination with conventional radiotherapy in non small cell lung cancer	5
PRINCE (TOURIST Platform)	PRINCE: Prospective, randomised, multicentre trial of first line systemic treatment and radiotherapy in stage IV non-small cell lung cancer	<5
QUARTZ LUNG (TOURIST Platform)	QUARTZ LUNG: Quality of life after radiotherapy treatment for patients with stage IV non-small cell lung cancer	0
REFINE-Lung	A randomised open-label phase III trial of Reduced Frequency pembrolizumab immuNothErapy for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) utilising a novel multi-arm frequency-response optimisation design	0

Some figures have been withheld and replaced with less than five (<5). This is because disclosure of small numbers may risk identifying individuals. The information is therefore exempt under Section 40(2) of the Freedom of Information Act 2000 - Personal Information relating to a third party. Its release would contravene the data protection principles set out in the UK GDPR.